Lefamulin acetate is under clinical development by Nabriva Therapeutics and currently in Phase II for Complicated Skin And Skin Structure Infections (cSSSI). According to GlobalData, Phase II drugs for Complicated Skin And Skin Structure Infections (cSSSI) have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lefamulin acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lefamulin acetate overview
Lefamulin Acetate or Lefamoren Acetate (Xenleta) belongs to pleuromutilin and derivatives is an antibiotic drug. It is formulated as film coated tablets for oral and concentrate solution for intravenous route of administration. Xenleta is indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms such as Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae,Legionella pneumophila, Mycoplasma pneumoniae, Chlamydophila pneumoniae and cystic fibrosis.
Lefamulin (BC-3781) is under development for the treatment of community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI) in adults and pediatrics and and LPS induced lung neutrophilia. BC-3781 is a semi-synthetic pleuromutilin antimicrobial agent which is developed as an intravenous and oral therapy. The drug candidate targets 23S rRNA of the 50S bacterial ribosome subunit. The drug candidate was also under development for multi-drug resistant sexually transmitted infections (STIs), including N. gonorrhoeae and M. genitalium, ventilator-associated bacterial pneumonia (VABP), hospital-acquired bacterial pneumonia (HABP), osteomyelitis and prosthetic joint infections.
Nabriva Therapeutics overview
Nabriva Therapeutics (Nabriva) is a biopharmaceutical company that researches and develops anti-infective agents for the treatment of infections. The company offers product candidates such as Xenleta (lefamulin), and CONTEPO (fosfomycin), being developed in both intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia. Its other pipeline products comprise BC-7013 for the topical treatment of a variety of gram-positive infections including uncomplicated skin and skin structure infections and Contepo to treat urinary tract infections. It partners with pharmaceutical and biotechnology companies. It has an operational presence in Austria, Ireland and the US. Nabriva is headquartered in Dublin, Ireland.
For a complete picture of Lefamulin acetate’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
